1. Home
  2. HIPO vs GLUE Comparison

HIPO vs GLUE Comparison

Compare HIPO & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIPO
  • GLUE
  • Stock Information
  • Founded
  • HIPO 2015
  • GLUE 2019
  • Country
  • HIPO United States
  • GLUE United States
  • Employees
  • HIPO N/A
  • GLUE N/A
  • Industry
  • HIPO Property-Casualty Insurers
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIPO Finance
  • GLUE Health Care
  • Exchange
  • HIPO Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • HIPO 440.1M
  • GLUE 356.3M
  • IPO Year
  • HIPO N/A
  • GLUE 2021
  • Fundamental
  • Price
  • HIPO $26.65
  • GLUE $5.69
  • Analyst Decision
  • HIPO Buy
  • GLUE Buy
  • Analyst Count
  • HIPO 3
  • GLUE 3
  • Target Price
  • HIPO $28.00
  • GLUE $12.67
  • AVG Volume (30 Days)
  • HIPO 166.8K
  • GLUE 1.2M
  • Earning Date
  • HIPO 03-05-2025
  • GLUE 03-13-2025
  • Dividend Yield
  • HIPO N/A
  • GLUE N/A
  • EPS Growth
  • HIPO N/A
  • GLUE N/A
  • EPS
  • HIPO N/A
  • GLUE N/A
  • Revenue
  • HIPO $334,700,000.00
  • GLUE $14,975,000.00
  • Revenue This Year
  • HIPO N/A
  • GLUE N/A
  • Revenue Next Year
  • HIPO $22.09
  • GLUE N/A
  • P/E Ratio
  • HIPO N/A
  • GLUE N/A
  • Revenue Growth
  • HIPO 84.92
  • GLUE N/A
  • 52 Week Low
  • HIPO $8.68
  • GLUE $3.21
  • 52 Week High
  • HIPO $34.24
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • HIPO 49.44
  • GLUE 35.93
  • Support Level
  • HIPO $22.83
  • GLUE $5.51
  • Resistance Level
  • HIPO $28.38
  • GLUE $6.38
  • Average True Range (ATR)
  • HIPO 1.31
  • GLUE 0.48
  • MACD
  • HIPO 0.13
  • GLUE -0.05
  • Stochastic Oscillator
  • HIPO 68.78
  • GLUE 14.90

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the Company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: